Trial Profile
Safety and tolerability of lenalidomide consolidation post allogeneic stem cell transplant for patients with high risk multiple myeloma failing to achieve stringent Complete Response
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2019
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 08 Oct 2019 Status changed from recruiting to completed.
- 05 Jul 2016 New trial record